瑞银发表研究报告指,诺诚健华(09969.HK) 去年下半年收入及纯利分别为16亿元人民币(下同)及6.73亿元,大致符合初步业绩。2025年全年收入按年增长135.3%至23.7亿元,纯利为6.43亿元,对比2024年录得亏损4.41亿元。产品销售毛利率按年提升0.5个百分点至86.8%,连同首付款带动整体毛利率按年提升5.7个百分点至92%。研发开支按年增长16.9%至9.52亿元,占产品销售...
Source Link瑞银发表研究报告指,诺诚健华(09969.HK) 去年下半年收入及纯利分别为16亿元人民币(下同)及6.73亿元,大致符合初步业绩。2025年全年收入按年增长135.3%至23.7亿元,纯利为6.43亿元,对比2024年录得亏损4.41亿元。产品销售毛利率按年提升0.5个百分点至86.8%,连同首付款带动整体毛利率按年提升5.7个百分点至92%。研发开支按年增长16.9%至9.52亿元,占产品销售...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.